Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas

Inclusion Criteria: * Age \>/= 18 years at the time of informed consent * Be capable, willing, and able to provide written informed consent/assent * Be willing to comply with clinical trial instructions and requirement, including mandatory biopsies * Dose escalation phase: Patients must have a histologically confirmed metastatic and/or locally advanced high grade sarcoma * Dose expansion phase: Patients must have a histologically confirmed metastatic and/or locally undifferentiated pleomorphic sarcoma, myxofibrosarcoma, leiomyosarcoma, or dedifferentiated liposarcoma * Adequate performance status: ECOG 0 or 1/KPS 100-70% * Patients must have at least one prior line of systemic therapy (e.g. chemotherapy, targeted or biological therapy) for their sarcoma. Prior neoadjuvant and/or adjuvant therapy will count regardless of when it was completed. Treatment naïve patients can enroll if they refuse standard of care systemic chemotherapy. * Presence of measurable disease per RECIST v1.1. Target lesions must not be chosen from a previously irradiated field unless there has been radiographically and/or pathologically documented tumor progression in that lesion prior to enrollment * Adequate organ function determined within 28 days of treatment initiation, as defined in Table 3: Table 3: Laboratory values inclusion criteria Hematological Absolute neutrophil count (ANC): ≥1,500 / mcL Platelets: ≥ 100,000 / mcL Hemoglobin: ≥ 9 g/dL or ≥ 5.6 mmol/L Renal Serum Creatinine OR Measured …